Search Results 771-780 of 17381 for alopecia

1. Mayo Clinic

   An experienced team of pediatric cancer experts diagnose and treat children who have brain tumors.

2. Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer - Mayo Clinic

   Residual CTCAE ≥ Grade 2 toxicity from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 neuropathy. Known history of HIV ...

3. My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors - Mayo Clinic

   ... alopecia; Radiation therapy within ≤ 14 days; Active or untreated brain metastases; History of carcinomatous meningitis; Uncontrolled concurrent malignancy ...

4. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

   Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Females of ...

5. A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM - Mayo Clinic

   current) related to prior anticancer therapy (excluding alopecia, lymphopenia, peripheral neuropathy, and ototoxicity, which are excluded only if ≥ Grade 3) ...

6. Women's health Women's health - Mayo Clinic

   Understand women's health issues, including leading health risks, menopause, breast health and more.

7. A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician’s choice chemotherapy, for the treatment of participants with metastatic HER2-positive breast cancer - Mayo Clinic

   Alopecia; Neuropathy resolved to ≤ Grade 2; Congestive heart failure that was ≤ Grade 1 in severity at the time of occurrence and resolved completely. Has ...

8. A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma - Mayo Clinic

   Toxicities due to prior therapy must be stable and recovered to Grade 1 or less (except for clinically non-significant toxicities such as alopecia). Age 18 ...

9. Mayo Clinic

   Students have full access to Heritage Student Center.

10. Jessica's Story - Mayo Clinic

    ... . VID-20466619. Home; Jessica's Story. Double your impact on cancer! Give Now. Make a gift before July 31 and it can be doubled in impact thanks to a ...